Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy

Multiple Sclerosis

Volumn 8, Issue 1, 2002, Pages 15-18

  Reess J ^a   Haas, J ^b   Gabriel, K ^c   Fuhlrott, A ^c   Fiola, M ^c  

^a Clinic for Neurology Dietenbronn   (Germany)

^b Jewish Hospital Berlin   (Germany)

^c Biogen GmbH   (Germany)

Author keywords

Adverse events; Antipyretics; Human; Interferon; Interferon beta 1a; Multiple sclerosis; Side effects

Indexed keywords

BETA1A INTERFERON; IBUPROFEN; PARACETAMOL; STEROID;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; PATIENT SATISFACTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM;

ACETAMINOPHEN; ADULT; CHILLS; FEMALE; FEVER; HEADACHE; HUMANS; IBUPROFEN; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 18244376902     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458502ms771sr     Document Type: Article

References (12)

1. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
2. Multiple sclerosis: Side effects of interferon beta therapy and their management
3. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis
4. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis
5. Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference
6. Managing the adverse effects of interferon-β therapy in multiple sclerosis
7. Ibuprofen treatment versus gradual introduction of interferon β-1b in patients with MS
8. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a
9. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis
10. Synergistic immunomodulatory effects of interferon-β-1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis
11. Low-dose steroids reduce flu-like symptoms at the initiation of IFNβ-1b in relapsing-remitting MS
12. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS